ClinicalTrials.gg
CompletedNCT02251223Updated Sep 29, 2014

Effects of Tipranavir/Ritonavir on the Pharmacokinetic Characteristics of Triple Drug Nucleoside and Non-nucleoside Reverse Transcriptase Inhibitor Therapy in HIV-1-infected Subjects

A Phase 1/2 interventional study of Tipranavir low dose and Tipranavir medium dose in HIV Infections, sponsored by Boehringer Ingelheim. Completed. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2014-09-29.

Sponsored by Boehringer Ingelheim · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
208
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 67 studies in HIV Infections by Boehringer Ingelheim — none open to participants now, none under way, none of them phase 3. HIV Infections · Boehringer Ingelheim.

Enrollment
14th of 46
208 · median 82
Started
2001
with 3 others
Phase 1/2
2 of 67
none open now
Registered
67th of 67
by date

Among the 67 studies in HIV Infections by Boehringer Ingelheim, this one is the 14th largest by enrollment of the 46 interventional ones that give a count, is one of 4 that started in 2001, is one of 2 in phase 1/2, and was the 67th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

None of the 67 studies in HIV Infections by Boehringer Ingelheim is open now. The open studies under HIV Infections, anywhere →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 67 studies in HIV Infections by Boehringer Ingelheim as a file.
02

Study summary

Primary: Sequentially determine the effects of three dose combinations of tipranavir (TPV) / ritonavir (RTV) (administered b.i.d.), TPV 1250 mg/RTV 100 mg vs. TPV 750 mg/RTV 100 mg vs. TPV 250 mg/RTV 200 mg on the steady-state pharmacokinetics of zidovudine, lamivudine, stavudine, didanosine, abacavir, nevirapine and efavirenz at approved doses. The three treatment groups will be enrolled sequentially starting with the highest tipranavir dosage group first and ending with the lowest tipranavir dosage group.

Secondary: A) To assess the effects of zidovudine, lamivudine, stavudine, didanosine, abacavir, nevirapine, and efavirenz on the pharmacokinetics of tipranavir/ritonavir compared to historical controls.

B) To assess the safety of three tipranavir/ritonavir combinations when used in combination with protocol defined antiretrovirals.

03

Conditions studied

  • HIV Infections

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed prior to trial participation
  2. Between 18 and 75 years of age inclusive
  3. Female subjects of child bearing potential are required to use a barrier method for at least 12 weeks prior to administration of study medication, during study medication administration, and for 28 days after the end of the study
  4. Ability to swallow capsules without difficulty
  5. A (BMI) between 11 and 50 kg/m2
  6. Reasonable probability for completion of the study
  7. Acceptable screening laboratory values. All laboratory values ≤ Grade I (e.g., creatine phosphokinase (CPK), amylase, triglycerides) are permissible if documentation of stability for 2 months or more is available. Abnormalities > Grade I are subject to approval by BI clinical monitor or designee
  8. Acceptable medical history, physical examination, , and chest X-ray prior to entering the treatment phase of the study
  9. Willingness to abstain from alcohol from Day -2 to Day 23
  10. Willingness to abstain from ingesting grapefruit, grapefruit juice, Seville oranges or orange marmalade from Day -2 to Day 23
  11. Negative urine drug screen for drugs of abuse. Subjects on methadone or equivalent narcotic maintenance programs will be permitted to enter the study
  12. Documented -1 RNA load (by PCR) at screening of ≤20,000 copies/mL for at least twelve weeks. Acceptable documentation would include laboratory data, a letter or a verbal report from another provider noted in the subject records.
  13. Stable doses of approved NRTIs and NNRTIs 2 for a minimum of twelve weeks prior to study Day 0. Subjects on efavirenz must be able to tolerate daily morning (8:00 a.m.) dosing starting at screening period and for 22 days of the study. Subjects receiving bid ddI must be willing to accept a change to the once a day delayed release (EC) formulation

Exclusion criteria

Exclusion Criteria:

  1. Female subjects who:

    • have a positive serum pregnancy test at Screening Period Day -14 to -7
    • are breast feeding
  2. Receipt of any other medicine for 30 days prior to Day 0
  3. Receipt of any known cytochrome P450 3A4 () altering drug i.e. phenothiazines, cimetidine, barbiturates, ketoconazole, fluconazole, rifampin, and herbal medications for 30 days prior to Day 0. No antibiotics permitted within 10 days prior to Day 0
  4. Ingestion of grapefruit, grapefruit juice, Seville oranges or orange marmalade within 2 days of study entry (Day 0)
  5. Blood or plasma donations (>100 ml total) for research or altruistic reasons within 30 days prior to Day 0
  6. Seated systolic blood pressure either \<100 mm Hg or >150 mm Hg; resting heart rate either \<50 beats/minute or >90 beats/minute
  7. History of any illness, including malabsorption, irregular food intake or gastrointestinal intolerance, or allergy that, in the opinion of the investigator, might confound the results of the study or pose additional risk in administering TPV/RTV
  8. Any acute illness within 2 weeks prior to Day 0
  9. Subjects who are currently taking any over-the-counter drug within 7 days prior to Day 0, or who are currently taking any prescription drug that, in the opinion of the investigator (in consultation with the BI medical monitor and/or pharmacokineticist), might interfere with either the absorption, distribution or metabolism of the TPV/RTV
  10. to TPV, RTV or sulfonamide containing drugs
  11. Using the adherence diary, subject has less than 100% documented adherence for the last 14 doses (7 days) of baseline antiretroviral medications prior to Day 0. Subjects has less than 100% adherence for the last 7 doses (7 days) of efavirenz and ddI (delayed release) prior to Day 0
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Enrollment
208 participants (actual)

Study arms

  • Experimental
    TPV/r low dose

    Drug: Tipranavir low dose · Drug: Ritonavir high dose

  • Experimental
    TPV/r medium dose

    Drug: Tipranavir medium dose · Drug: Ritonavir low dose

  • Experimental
    TPV/r high dose

    Drug: Tipranavir high dose · Drug: Ritonavir low dose

Interventions

  • DrugTipranavir low dose
  • DrugTipranavir medium dose
  • DrugTipranavir high dose
  • DrugRitonavir low dose
  • DrugRitonavir high dose
06

What researchers measure

Primary outcomes

  1. Change in trough plasma concentration (Cmin,ss) for non-nucleoside reverse transcriptase inhibitor (NNRTI)

    stratified by substance

    Time frame: baseline, up to day 23

  2. Change in area under plasma concentration-time curve over dosing interval (AUC0-τ) for nucleoside reverse transcriptase inhibitor (NRTI)

    stratified by substance

    Time frame: baseline, up to day 22

  3. Change in area under plasma concentration-time curve from 0 to 12 hours for didanosine (ddI)

    Time frame: baseline, up to day 22

Secondary outcomes

  1. Cmin,ss

    stratified by substance

    Time frame: up to day 23

  2. AUC0-τ

    stratified by substance

    Time frame: up to day 23

  3. Maximum plasma concentration (Cmax)

    stratified by substance

    Time frame: up to day 23

  4. Time of maximum plasma concentration (Tmax)

    stratified by substance

    Time frame: up to day 23

  5. Oral clearance (Cl/F)

    stratified by substance

    Time frame: up to day 23

  6. Apparent terminal half life (t1/2)

    stratified by substance

    Time frame: up to day 23

  7. Change in CD4 cell count

    Time frame: up to day 23

  8. Change in HIV-1 RNA levels

    Time frame: up to day 23

  9. Number of patients with clinically significant findings in laboratory tests

    Time frame: up to 25 weeks

  10. Number of patients with adverse events

    Time frame: up to 25 weeks

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2001 and a primary completion of Feb 2002. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2014
First posted
Sep 29, 2014
Start
Feb 2001
Primary completionActual
Feb 2002
Last update
Sep 29, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 29, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02251223
Responsible party
Sponsor
First posted
Sep 29, 2014
Start date
Feb 2001
Primary completion
Feb 2002
Last update
Sep 29, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion